Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Crb-601 Monoclonal Antibody, Anti-Pd-1 Monoclonal Antibody
Solid Tumor
Phase I/II
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Sep 13, 2024
―
Crb-701, Anti-Pd-1
Solid Tumor, Adult
Phase I/II
Recruiting
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Feb 08, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Corbus Pharmaceuticals (CRBP) have in its pipeline
CRBP is currently developing the following drugs: Crb-601 Monoclonal Antibody, Anti-Pd-1 Monoclonal Antibody, Crb-701, Anti-Pd-1. These drug candidates are in various stages of clinical development as the company works toward FDA approval.